| |||||||||||||
|
Home
|
For other articles and previous issues click here. October 24, 2005
Coding
for Respiratory Distress Syndrome Respiratory distress syndrome (RDS)
typically occurs in premature infants but is rare in full-term infants. The
disease is caused by a lack of pulmonary surfactant, a chemical normally produced
by the lung that spreads like a film over the tiny air sacs, allowing them to
stay open. Infections and insufficient oxygen in the blood can also cause RDS. Types
of RDS • cardiorespiratory distress
syndrome of newborn; • hyaline membrane disease; • idiopathic respiratory distress
syndrome of newborn; • infantile or infant respiratory
distress syndrome; • neonatal respiratory distress
syndrome; and • pulmonary hypoperfusion
syndrome. Type II RDS is also called transient
tachypnea of the newborn (TTN), classified by fast breathing that gradually
gets better. It is caused by slow reabsorption of fetal lung fluid. TTN is more
common in babies delivered by cesarean section because they did not have fluid
squeezed out with delivery. TTN is mild and usually resolves within six to 24
hours of birth (AHA Coding Clinic for ICD-9-CM, 1989, first quarter, page 10;
1986, N/D, page 6). However, it may not resolve for 24 to 48 hours after birth
or even longer. If the physician documents TTN but the condition lasted longer
than two days, still assign the code for TTN (770.6) based on the physician’s
documentation and not the time frame of the condition (AHA Coding Clinic for
ICD-9-CM, 1993, third quarter, page 7). Signs
and Symptoms of RDS • tachypnea/rapid breathing; • intercostals retractions
(pulling in of the ribs and sternum with each breath); • shortness of breath; • nasal flaring; • grunting; • cessation of breathing; • cyanosis; • acidosis; • respiratory distress; and • atelectasis. Diagnosis
of RDS Treatment
of RDS If it is determined that premature
birth is unavoidable, the mother may take corticosteroids 48 to 72 hours before
delivery to stimulate the baby’s lungs to produce surfactant. After delivery,
the baby may take a surfactant directly into the lungs through an endotracheal
tube. A baby must be intubated to receive surfactant, and it is most effective
if started within six hours of birth. These drugs can sometimes prevent
RDS from developing or decrease its severity. Some surfactants include beractant
(Survanta), poractant alfa (Curosurf), calfactant (Infasurf), and Exosurf Neonatal
(a synthetic product that combines colfosceril palmitate, cetyl alcohol, and
tyloxapol). It has been shown that surfactants can reduce mortality from RDS,
which typically worsens over the first two to three days after birth and then
improves with treatment. Complications • cardiac arrest (779.89); • pneumothorax (770.2); • pneumomediastinum (770.2); • pneumopericardium (770.2); • pulmonary interstitial emphysema
(770.2); • bronchopulmonary dysplasia
(770.7); • intraventricular bleed (772.1x); • hemorrhage into the lung
(770.3); and • delayed mental development
(315.9). Signs and
Symptoms of TTN • rapid breathing; • grunting; and • nostril flaring. Treatment
of TTN If a newborn presents with many
of the signs and symptoms listed under RDS and is being treated with oxygen,
ventilator, or surfactants—but the physician did not document RDS (or
any other synonymous term)—then the physician should be asked to clarify
the diagnosis. Because TTN has some of the same signs and symptoms as RDS, it
will be important to obtain physician documentation of the appropriate diagnosis. Coding and sequencing for RDS are
dependent on the physician documentation in the medical record and application
of the Official Coding Guidelines for inpatient care. Also, use specific AHA
Coding Clinic for ICD-9-CM and American Medical Association CPT Assistant references
to ensure complete and accurate coding. — This information
was prepared by Audrey Howard, RHIA, of 3M Health Information Systems (800-367-2447),
a supplier of coding and classification systems to nearly 5,000 healthcare providers.
The company and its representatives do not assume any responsibility for reimbursement
decisions or claims denials made by providers or payors as the result of the
misuse of this coding information. |
![]() |
3801 Schuylkill Rd • Spring City, PA 19475 Publishers of For the Record All rights reserved. |